EUVIMEDEUVIMED entdecken
StudienprotokollOpen Access · CC BY 4.0

Randomised, double-blind study to evaluate the efficacy of rituximab in the treatment of idiopathic membranous nephropathy: A clinical trial protocol

Shinobu Shimizu iD, Akihito Tanaka iD, Nao Matsuyama, Fumie Kinoshita, Kazuhiro Furuhashi, Shoichi Maruyama iD, PRIME Study Group

PLOS ONE · 2025

DOI: 10.1371/journal.pone.0320070 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift PLOS ONE, 2025. Verfasst von Shinobu Shimizu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Advanced Medicine, Nagoya University Hospital, Nagoya, Aichi, Japan. Hauptthemen laut MEDLINE: Glomerulonephritis, Membranous, Nephrotic Syndrome, Rituximab. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Agency for Medical Research and Development, Nippon Zenyaku Kogyo.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In Japan, corticosteroid monotherapy has traditionally been recommended as the first-line therapy for membranous nephropathy with nephrotic syndrome. In contrast, except for Japan, rituximab is recommended as the first-line therapy for membranous nephropathy with nephrotic syndrome. This clinical trial aimed to verify the efficacy and safety of the intravenous administration of rituximab without steroids or immunosuppressants as an induction therapy in Japanese patients with idiopathic membranous nephropathy and nephrotic syndrome. This was a multicentre (15 in Japan), placebo-controlled, randomized, double-blind, parallel-group comparative study. A total of 88 patients diagnosed with idiopathic membranous nephropathy and nephrotic syndrome were randomly allocated to rituximab and placebo groups in a 1:1 ratio; rituximab 1,000 mg or placebo IV infusion was administered every 2 weeks for two doses in a double-blinded manner. The primary endpoint was the percentage of patients achieving less than 1.0 g/g creatinine in urine protein/creatinine ratio in random urine at 26 weeks after the first administration of rituximab or placebo. This study was approved by the institutional review boards and conducted in accordance with the Good Clinical Practice guidelines. This study was registered at ClinicalTrials.gov, NCT05914155 and the Japan Registry of Clinical Trials, jRCT2041230037 on 13 June 2023.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glomerulonephritis, MembranousNephrotic SyndromeRituximabAdultAgedFemaleHumansMaleMiddle AgedDouble-Blind MethodJapanRandomized Controlled Trials as TopicTreatment OutcomeMulticenter Studies as Topic

Substanzen

Rituximab

Autor:innen und Institutionen

  • Department of Advanced Medicine, Nagoya University Hospital, Nagoya, Aichi, Japan.
  • Department of Nephrology, Nagoya University Hospital, Nagoya, Aichi, Japan.
  • Department of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan.

ORCID-Profile: Shinobu Shimizu, Akihito Tanaka, Shoichi Maruyama

Förderung

  • Japan Agency for Medical Research and Development
  • Nippon Zenyaku Kogyo

Zitieren

APA

Shimizu, S., Tanaka, A., Matsuyama, N., Kinoshita, F., Furuhashi, K., Maruyama, S., & PRIME Study Group (2025). Randomised, double-blind study to evaluate the efficacy of rituximab in the treatment of idiopathic membranous nephropathy: A clinical trial protocol. PLOS ONE. https://doi.org/10.1371/journal.pone.0320070

Vancouver

Shimizu S, Tanaka A, Matsuyama N, Kinoshita F, Furuhashi K, Maruyama S, et al. Randomised, double-blind study to evaluate the efficacy of rituximab in the treatment of idiopathic membranous nephropathy: A clinical trial protocol. PLOS ONE. 2025. doi:10.1371/journal.pone.0320070

BibTeX
@article{Shimizu2025,
  author = {Shimizu, Shinobu and Tanaka, Akihito and Matsuyama, Nao and Kinoshita, Fumie and Furuhashi, Kazuhiro and Maruyama, Shoichi and PRIME Study Group, PRIME Study Group},
  title = {Randomised, double-blind study to evaluate the efficacy of rituximab in the treatment of idiopathic membranous nephropathy: A clinical trial protocol},
  journal = {PLOS ONE},
  year = {2025},
  doi = {10.1371/journal.pone.0320070}
}
Kostenlos starten →